Suglat
(Ipragliflozin)ApprovedSmall molecule
AstellasIpragliflozin is used to treat type 2 diabetes by helping the kidneys remove excess sugar through urine, which lowers blood sugar levels.[2] Suglat is currently approved and in use across 6 indications[4].[1]
Suglat is one of 191 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Approved.
6
Indications
26
Total Trials
0
Active Trials
190
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Suglat
AstellasApproved
Jardiance
Boehringer IngelheimPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Acipimox
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus11 trials
Show 8 more trials
Type 2 Diabetic Patients5 trials
Type 2 Diabetes3 trials
Safety and Efficacy2 trials
4 more indications
Type 1 Diabetes Mellitus1 trial
Clinical Efficacy and Safety1 trial
Non-Alcoholic Fatty Liver Disease1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Suglat drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ipragliflozin. EMBL-EBI & Wellcome Sanger Institute.
- [5]